Keeps Biopharma

Company	Business Area		Product	Indication	Feasibility	Pre-clinical	Phase 1	Phase 2	Phase 3	Remark
Company	Business Area		Product	Indication	Reasearch	Development	Proof of Concept	Pilot Study	Pivotal Study	Remark
Algokbio	Cancer therapeutics
Algokbio		TM4SF4 antibody therapy	AGK-102	Lung / Liver / Pancreatic cancer	-	-				First-in-class cancer stem cell biomarker target
BIXINK		HER2 targeted therapy	NERLYNX®	Early breast cancer	-	-	-	-	-	MFDS Approval, 4Q 2021 / Launch, 1Q 2022
	Cancer supportive care	Adhesion fluid-gel type wound dressing	Mucosamin ^TM	Radio/Chemotherapy-induced mucositis and dry mouth	-	-	-	-	-	MFDS regulatory submission
	Digital therapeutics	Exposure and response prevention	OC Free®	Obsessive compulsive disorder	-	-	-	-
		Cognitive behavioral therapy	SparkRx ^TM	Adolescent depression	-	-	-	-
		Cognitive behavioral stress management	attune ^TM	Cancer-related symptoms of anxiety and depression	-	-	-	-		Breakthrough device designation by FDA, 2020
		Cognitive behavioral stress management	DreAMLand ^TM	Cancer-related symptoms of anxiety and depression(AML-specific)	-	-	-	-		Breakthrough device designation by FDA, 2022
	Digital healthcare management	Symptom tracking and medication management	WEPEACH®	Breast cancer patients supportive care	-	-	-	-	-	Launch, 2Q 2021
KPS BIO	Diagnostics	Multiple biomarker panel	KPS-101	Early diagnosis of hepatocellular carcinoma	-	-	-	-		Published in SCI-E journal, 2Q 2022
		Companion diagnostics	KPS-102	Blood cancer	-
		Companion diagnostics	KPS-103	Lung cancer(TM4SF4)	-
		Circulating tumor cell isolation	KPS-104	Automation equipment(Label-dependent)	-	-
		Circulating tumor cell isolation	KPS-105	Automation equipment(Label-free)	-	-
	CDMO	Incrementally modified drug	KPT-101	Inflammatory bowel disease	-
		First generic	KPT-102	Irritable bowel syndrome with constipation	-
			KPT-103	Irritable bowel syndrome with diarrhea	-
			KPT-104	Idiopathic pulmonary fibrosis	-

Drug

Medical device/In Vitro Diagnostic

TOP